CD274 and small cell lung carcinoma: In addition to PARPi, treatment with a combination of the CHK1i SRA737 and the antimetabolite agent gemcitabine plus anti-PD-L1/anti-PD-1 also decreased MDSCs in a small cell lung cancer (SCLC) model [22].